abstract: BACKGROUND: Immunosuppression medications contribute to posttransplant @entity6 in @entity1 and can cause insulin resistance in male @entity35 . @entity1140 ( @entity11636 )- @entity3446 (SIR) immunosuppression is also associated with appearance of @entity42 in transplant @entity1 . Because insulin resistance is observed in @entity1 with @entity3610 , we hypothesized that @entity11636 or SIR may induce @entity854 . METHODS: We monitored estrus cycles of adult female @entity35 treated daily with @entity11636 , SIR, and combination of @entity11636 -SIR, or diluent (control) for 4 weeks. Animals were then challenged with oral @entity413 to determine their @entity413 and insulin responses, killed, and their blood and tissues, including ovaries and uteri harvested. RESULTS: @entity11636 and @entity11636 -SIR treatments increased mean random @entity413 concentrations (P<0.05). @entity11636 , SIR, and @entity11636 -SIR treatments also increased the @entity413 response to oral @entity413 challenge (P<0.05). The insulin response to @entity413 was significantly higher in @entity35 treated with SIR compared with @entity11636 (P<0.05). @entity11636 , SIR and @entity11636 -SIR treatments reduced number of estrus cycles (P<0.05). The ovaries were smaller after SIR and @entity11636 -SIR treatment compared with controls. The @entity11636 and @entity11636 -SIR treatment groups had fewer preovulatory follicles. Corpora lutea were present in all groups. Ovarian aromatase expression was reduced in the SIR and @entity11636 -SIR treatment groups. A significant (P<0.05) reduction in uterine size was observed in all treatment groups when compared with controls. CONCLUSION: In a model of immunosuppressant-induced @entity4854 , both @entity11636 and SIR induced @entity854 in adult female @entity35 , likely through different mechanisms.

title: @entity1140 and @entity3446 induce XXXX in female @entity35 .

entities_list: @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovary syndrome']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus']

entities_list: @entity42 :: ('MESH:D010048', 'Disease') :: ['ovarian cysts']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['reproductive abnormalities']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['Tacrolimus']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity854 :: (MESH:D018376,Disease) :: ['reproductive abnormalities']


abstract: BACKGROUND: Immunosuppression medications contribute to posttransplant @entity6 in @entity1 and can cause insulin resistance in male @entity35 . @entity1140 ( @entity11636 )- @entity3446 (SIR) immunosuppression is also associated with appearance of @entity42 in transplant @entity1 . Because insulin resistance is observed in @entity1 with @entity3610 , we hypothesized that @entity11636 or SIR may induce @entity854 . METHODS: We monitored estrus cycles of adult female @entity35 treated daily with @entity11636 , SIR, and combination of @entity11636 -SIR, or diluent (control) for 4 weeks. Animals were then challenged with oral @entity413 to determine their @entity413 and insulin responses, killed, and their blood and tissues, including ovaries and uteri harvested. RESULTS: @entity11636 and @entity11636 -SIR treatments increased mean random @entity413 concentrations (P<0.05). @entity11636 , SIR, and @entity11636 -SIR treatments also increased the @entity413 response to oral @entity413 challenge (P<0.05). The insulin response to @entity413 was significantly higher in @entity35 treated with SIR compared with @entity11636 (P<0.05). @entity11636 , SIR and @entity11636 -SIR treatments reduced number of estrus cycles (P<0.05). The ovaries were smaller after SIR and @entity11636 -SIR treatment compared with controls. The @entity11636 and @entity11636 -SIR treatment groups had fewer preovulatory follicles. Corpora lutea were present in all groups. Ovarian aromatase expression was reduced in the SIR and @entity11636 -SIR treatment groups. A significant (P<0.05) reduction in uterine size was observed in all treatment groups when compared with controls. CONCLUSION: In a model of immunosuppressant-induced @entity4854 , both @entity11636 and SIR induced @entity854 in adult female @entity35 , likely through different mechanisms.

title: @entity1140 and XXXX induce @entity854 in female @entity35 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity3446 :: (MESH:D020123,Chemical) :: ['sirolimus']


abstract: BACKGROUND: Immunosuppression medications contribute to posttransplant @entity6 in @entity1 and can cause insulin resistance in male @entity35 . @entity1140 ( @entity11636 )- @entity3446 (SIR) immunosuppression is also associated with appearance of @entity42 in transplant @entity1 . Because insulin resistance is observed in @entity1 with @entity3610 , we hypothesized that @entity11636 or SIR may induce @entity854 . METHODS: We monitored estrus cycles of adult female @entity35 treated daily with @entity11636 , SIR, and combination of @entity11636 -SIR, or diluent (control) for 4 weeks. Animals were then challenged with oral @entity413 to determine their @entity413 and insulin responses, killed, and their blood and tissues, including ovaries and uteri harvested. RESULTS: @entity11636 and @entity11636 -SIR treatments increased mean random @entity413 concentrations (P<0.05). @entity11636 , SIR, and @entity11636 -SIR treatments also increased the @entity413 response to oral @entity413 challenge (P<0.05). The insulin response to @entity413 was significantly higher in @entity35 treated with SIR compared with @entity11636 (P<0.05). @entity11636 , SIR and @entity11636 -SIR treatments reduced number of estrus cycles (P<0.05). The ovaries were smaller after SIR and @entity11636 -SIR treatment compared with controls. The @entity11636 and @entity11636 -SIR treatment groups had fewer preovulatory follicles. Corpora lutea were present in all groups. Ovarian aromatase expression was reduced in the SIR and @entity11636 -SIR treatment groups. A significant (P<0.05) reduction in uterine size was observed in all treatment groups when compared with controls. CONCLUSION: In a model of immunosuppressant-induced @entity4854 , both @entity11636 and SIR induced @entity854 in adult female @entity35 , likely through different mechanisms.

title: XXXX and @entity3446 induce @entity854 in female @entity35 .

answer: @entity1140 :: (MESH:D016559,Chemical) :: ['Tacrolimus']


abstract: BACKGROUND: Immunosuppression medications contribute to posttransplant @entity6 in @entity1 and can cause insulin resistance in male @entity35 . @entity1140 ( @entity11636 )- @entity3446 (SIR) immunosuppression is also associated with appearance of @entity42 in transplant @entity1 . Because insulin resistance is observed in @entity1 with @entity3610 , we hypothesized that @entity11636 or SIR may induce @entity854 . METHODS: We monitored estrus cycles of adult female @entity35 treated daily with @entity11636 , SIR, and combination of @entity11636 -SIR, or diluent (control) for 4 weeks. Animals were then challenged with oral @entity413 to determine their @entity413 and insulin responses, killed, and their blood and tissues, including ovaries and uteri harvested. RESULTS: @entity11636 and @entity11636 -SIR treatments increased mean random @entity413 concentrations (P<0.05). @entity11636 , SIR, and @entity11636 -SIR treatments also increased the @entity413 response to oral @entity413 challenge (P<0.05). The insulin response to @entity413 was significantly higher in @entity35 treated with SIR compared with @entity11636 (P<0.05). @entity11636 , SIR and @entity11636 -SIR treatments reduced number of estrus cycles (P<0.05). The ovaries were smaller after SIR and @entity11636 -SIR treatment compared with controls. The @entity11636 and @entity11636 -SIR treatment groups had fewer preovulatory follicles. Corpora lutea were present in all groups. Ovarian aromatase expression was reduced in the SIR and @entity11636 -SIR treatment groups. A significant (P<0.05) reduction in uterine size was observed in all treatment groups when compared with controls. CONCLUSION: In a model of immunosuppressant-induced @entity4854 , both @entity11636 and SIR induced @entity854 in adult female @entity35 , likely through different mechanisms.

title: @entity1140 and @entity3446 induce @entity854 in female XXXX .

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: INTRODUCTION: The @entity2795 pain is common after a @entity64 . Its appearance brings @entity158 and limits daily living activities as well as participation in specific Neuro-rehabilitation programs. All this leads to a worse functional outcome. Good management of @entity1 can reduce both the frequency and intensity of @entity158 , improving functional outcome. DEVELOPMENT: We conducted a literature search of various databases between 1980 and 2008. The articles were evaluated using the PEDro scoring system. Five evidence levels were established for the conclusions. CONCLUSIONS: Shoulder subluxation, occurs at an early stage after @entity64 and is associated with subluxation of the shoulder joint and @entity508 (mainly subscapularis and pectoralis). Slings prevent subluxation of the shoulder. It is preferable to move within a lower range of motion and without @entity146 to prevent the occurrence of @entity158 . The injection of @entity288 does not improve @entity158 and range of motion in hemiplegic @entity1 , while botulinum toxin combined with physical therapy appears to reduce @entity2795 pain.

title: [Painful @entity2795 in XXXX @entity1 : causes and management].

entities_list: @entity2795 :: ('MESH:D020325', 'Disease') :: ['hemiplegic shoulder']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggression']

entities_list: @entity508 :: ('MESH:D009128', 'Disease') :: ['spasticity']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'shoulder pain']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity64 :: (MESH:D020521,Disease) :: ['stroke']


abstract: INTRODUCTION: The @entity2795 pain is common after a @entity64 . Its appearance brings @entity158 and limits daily living activities as well as participation in specific Neuro-rehabilitation programs. All this leads to a worse functional outcome. Good management of @entity1 can reduce both the frequency and intensity of @entity158 , improving functional outcome. DEVELOPMENT: We conducted a literature search of various databases between 1980 and 2008. The articles were evaluated using the PEDro scoring system. Five evidence levels were established for the conclusions. CONCLUSIONS: Shoulder subluxation, occurs at an early stage after @entity64 and is associated with subluxation of the shoulder joint and @entity508 (mainly subscapularis and pectoralis). Slings prevent subluxation of the shoulder. It is preferable to move within a lower range of motion and without @entity146 to prevent the occurrence of @entity158 . The injection of @entity288 does not improve @entity158 and range of motion in hemiplegic @entity1 , while botulinum toxin combined with physical therapy appears to reduce @entity2795 pain.

title: [Painful XXXX in @entity64 @entity1 : causes and management].

answer: @entity2795 :: (MESH:D020325,Disease) :: ['hemiplegic shoulder']


abstract: INTRODUCTION: The @entity2795 pain is common after a @entity64 . Its appearance brings @entity158 and limits daily living activities as well as participation in specific Neuro-rehabilitation programs. All this leads to a worse functional outcome. Good management of @entity1 can reduce both the frequency and intensity of @entity158 , improving functional outcome. DEVELOPMENT: We conducted a literature search of various databases between 1980 and 2008. The articles were evaluated using the PEDro scoring system. Five evidence levels were established for the conclusions. CONCLUSIONS: Shoulder subluxation, occurs at an early stage after @entity64 and is associated with subluxation of the shoulder joint and @entity508 (mainly subscapularis and pectoralis). Slings prevent subluxation of the shoulder. It is preferable to move within a lower range of motion and without @entity146 to prevent the occurrence of @entity158 . The injection of @entity288 does not improve @entity158 and range of motion in hemiplegic @entity1 , while botulinum toxin combined with physical therapy appears to reduce @entity2795 pain.

title: [Painful @entity2795 in @entity64 XXXX : causes and management].

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Stigma associated with @entity378 ( @entity378 ) is often regarded as a barrier to health seeking and a cause of social suffering. Stigma studies are typically @entity1 -centred, and less is known about the views of communities where @entity1 reside. This study examined community perceptions of @entity378 . A total of 160 respondents (80 @entity1 and 80 @entity1 ) without @entity378 in the general population of Western Maharashtra, India, were interviewed using Explanatory Model Interview Catalogue interviews with same-sex and cross-sex vignettes depicting a @entity1 with typical features of @entity378 . The study clarified features of @entity378 . Concealment of disease was explained as fear of losing social status, marital problems and hurtful behaviour by the community. For the female vignette, heredity was perceived as a cause for stigmatising behaviour. Marital problems were anticipated more for the male vignette. Anticipation of spouse support, however, was more definite for @entity1 and conditional for @entity1 , indicating the vulnerability of @entity1 . Community views acknowledged that both @entity1 and @entity1 with @entity378 share a psychological burden of unfulfilled social responsibilities. The distinction between public health risks of @entity281 and unjustified social isolation (stigma) was ambiguous. Such a distinction is important for effective community-based interventions for early diagnosis of @entity378 and successful treatment.

title: Gender and community views of stigma and XXXX , India.

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients', 'patient', 'person']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['TB-related stigma', 'TB', 'tuberculosis']

answer: @entity378 :: (MESH:D014376,Disease) :: ['tuberculosis in rural Maharashtra']


abstract: Spinal cord (SC) @entity194 , i.e. a reduction in the SC cross-sectional area (CSA) over time, can be measured by means of image segmentation using magnetic resonance imaging (MRI). However, segmentation methods have been limited by factors relating to reproducibility or sensitivity to change. The purpose of this study was to evaluate a fully automated SC segmentation method (PropSeg), and compare this to a semi-automated @entity3457 ( @entity3457 ) method, in healthy controls (HC) and @entity1 with @entity15 ( @entity15 ). MRI data from 120 @entity1 were retrospectively analysed; 26 HC, 21 with @entity922 , 26 relapsing remitting @entity15 , 26 primary and 21 secondary progressive @entity15 . MRI data from 40 @entity1 returning after one year were also analysed. CSA measurements were obtained within the cervical SC. Reproducibility of the measurements was assessed using the intraclass correlation coefficient (ICC). A comparison between mean CSA changes obtained with the two methods over time was performed using multivariate structural equation regression models. Associations between CSA measures and clinical scores were investigated using linear regression models. Compared to the @entity3457 method, the reproducibility of CSA measurements obtained with PropSeg was high, both in @entity1 and in HC, with ICC  >  0.98 in all cases. There was no significant difference between PropSeg and @entity3457 in terms of detecting change over time. Furthermore, PropSeg provided measures that correlated with @entity717 , similar to the @entity3457 method. PropSeg is a time-efficient and reliable segmentation method, which requires no manual intervention, and may facilitate large multi-centre neuroprotective trials in progressive @entity15 .

title: Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['physical disability']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis']

entities_list: @entity3457 :: ('OMIM:612348', 'Disease') :: ['AS', 'active surface']

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['clinically isolated syndrome']

answer: @entity15 :: (MESH:D009103,Disease) :: ['multiple sclerosis']


abstract: Clinical decision support (CDS) systems show promise for enhancing @entity1 safety, but they require rigorous evaluation before they can be implemented widely. We developed a software application for use with personal digital assistants (PDAs) that models @entity1 -specific dose responses to help physicians predict steady-state @entity1229 dosing requirements and steer @entity1 to a therapeutic level of anticoagulation as quickly and safely as possible. We also designed a randomized, controlled multi-site trial to evaluate the effectiveness of the @entity1229 Dosing and Communication System (WARFDOCS) in reducing @entity1229 -related errors. Numerous obstacles delayed implementation of the CDS system and completion of the trial. To better understand the causes that led to the delay, we interviewed key informants at participating hospitals; reviewed study protocols, administrative records, and meeting minutes; and held discussions to review the data and their interpretation. Salient themes were identified by consensus of the research team and these were corroborated by key informants. Four major themes emerged. First, agreement to participate in the trial reflected very different levels of commitment. Sites participating in CDS system evaluations must be managed actively. Second, the enthusiasm of end-users for a CDS system was derived from a complex calculus of perceived benefits and burdens. Unfortunately, the most relevant appeal (that such a system would markedly improve @entity1 safety) could not be made in advance of the trial. Third, research changes everything. Valid research procedures (e.g., informed consent, randomization, and intrusive data collection) may be necessary, but can themselves affect a key outcome of most CDS system evaluations: user uptake. Fourth, strong    center effects    (i.e., the CDS system proved effective at some sites, but not at others) should be expected. If    all politics is local,    then much of @entity1 safety research is localized as well.

title: From Insight to Implementation: Lessons from a Multi-site Trial of a PDA-based XXXX Dose Calculator

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin', 'Warfarin']

answer: @entity1229 :: (MESH:D014859,Chemical) :: ['Warfarin']


abstract: BACKGROUND AND STUDY AIMS: Endoscopic submucosal dissection (ESD) is a standard treatment for early @entity356 (EGC) without lymph node @entity3 . However, some @entity1 undergo noncurative ESD. The aim of the present study was to assess the long-term clinical outcomes of noncurative ESD with or without additional surgery. @entity1 AND METHODS: We investigated the chart data from all @entity1 who had undergone ESD for EGC at Saga Medical School Hospital and Saga Prefectural Medical Centre Koseikan between 2001 and 2012. A total of 957 cases (1047 lesions) of EGC underwent ESD, and 99 had noncurative ESD. In total, 20 cases were excluded because their follow-up period was <3 years. We divided the @entity1 into observation and additional surgery groups, and we compared the survival rate and related factors between the groups. RESULTS: After noncurative ESD, 28/79 @entity1 (35.4%) underwent additional surgery and 51/79 (64.6%) were followed up without surgery. The average age of @entity1 in the observation group was higher than that of the additional surgery group (75.9 vs. 71.6 years; P=0.03). The incidence of @entity101 was significantly higher in the observation group compared with the additional surgery group (51.0 vs. 25.9%; P=0.03). The overall survival rate of the additional surgery group was longer than that of the observation group.However, only one @entity1 died from @entity356 in the observation group.The disease-specific survival rate did not differ significantly between the groups. CONCLUSIONS: It might be acceptable to follow up without additional surgery for some @entity1 with comorbidity and who were elderly after noncurative ESD for EGC.

title: Effect of additional surgery after noncurative endoscopic submucosal dissection for early XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']


abstract: BACKGROUND AND STUDY AIMS: The treatment success of @entity253 with fully covered metal stents (CSEMS) is altered by high stent dislocation rates. We aimed to evaluate a new stent design to prevent dislocation. @entity1 AND METHODS: @entity1 with @entity253 were treated with a newly designed double-coned stent (dcSEMS). Mechanical analysis of the new stent was performed and it was compared with a cylindrical stent. RESULTS: A total of 13 dcCSEMS were implanted in 11 @entity1 (2 female, 9 male, median age 47, range 33-71). All @entity1 had @entity253 due to chronic @entity788 . No stent migration occurred. In all but one @entity1 the stents were removed. One @entity1 refused stent extraction and was lost to follow up. @entity432 occurred twice leading to @entity255 in both cases. The duration of stent treatment was 170 days (range 61-254). After extraction only one @entity1 had early recurrent stricture and received the same stent again. Three stents showed minimal tissue granulation at the papilla. One stent presented ingrowth at the proximal end and was removed after implantation of a second fully covered stent. Mechanical examination revealed significantly lower radial expansion force of the new stent as compared to the cylindrical stent. CONCLUSIONS: The new stent design has a low rate of migration. Biomechanical properties may explain this effect.

title: Anatomy-shaped design of a fully-covered, biliary, self-expandable metal stent for treatment of benign XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['Stent occlusion']

entities_list: @entity253 :: ('MESH:D001660', 'Disease') :: ['benign biliary strictures', 'distal biliary strictures']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']

answer: @entity253 :: (MESH:D001660,Disease) :: ['distal biliary strictures']


abstract: AIM: An association between body mass index (BMI) and @entity64 outcome have been reported, but the results are controversial. The aim of the present study was to evaluate whether BMI is associated with @entity385 outcome. METHODS: Consecutive Japanese acute @entity385 @entity1 were analyzed. BMI was categorized as underweight (BMI <18.5   kg/m(2) ), normal weight (18.5-24.9   kg/m(2) ) and @entity28 (>= 25   kg/m(2) ). BMI and short-term and long-term outcomes were examined. Short-term outcomes were evaluated using the modified Rankin scale score at hospitalization and discharge; modified Rankin scale >= 3 was defined as a poor outcome. Long-term outcomes were evaluated by all-cause mortality. The recurrence rate was also evaluated in each BMI group. Values of P   <   0.05 were considered significant. RESULTS: A total of 1206 acute @entity385 @entity1 (760 @entity1 ; mean age 72.5 years) were analyzed in the present study. There were 111 underweight cases (9.2%), 785 normal weight cases (65.1%) and 310 @entity28 cases (25.7%). The underweight group had a significantly higher rate of poor short and long-term outcomes than the normal weight group. The outcomes of the @entity28 group were not significantly different from those of the normal weight group. Recurrence was not significantly different among the groups. CONCLUSIONS: Lower BMI might be a predictor of poorer short-term and long-term @entity64 outcomes. Geriatr Gerontol Int 2016;       :       -      .

title: Association between body mass index and outcome in Japanese XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity385 :: (MESH:D002544,Disease) :: ['ischemic stroke']


abstract: AIM: An association between body mass index (BMI) and @entity64 outcome have been reported, but the results are controversial. The aim of the present study was to evaluate whether BMI is associated with @entity385 outcome. METHODS: Consecutive Japanese acute @entity385 @entity1 were analyzed. BMI was categorized as underweight (BMI <18.5   kg/m(2) ), normal weight (18.5-24.9   kg/m(2) ) and @entity28 (>= 25   kg/m(2) ). BMI and short-term and long-term outcomes were examined. Short-term outcomes were evaluated using the modified Rankin scale score at hospitalization and discharge; modified Rankin scale >= 3 was defined as a poor outcome. Long-term outcomes were evaluated by all-cause mortality. The recurrence rate was also evaluated in each BMI group. Values of P   <   0.05 were considered significant. RESULTS: A total of 1206 acute @entity385 @entity1 (760 @entity1 ; mean age 72.5 years) were analyzed in the present study. There were 111 underweight cases (9.2%), 785 normal weight cases (65.1%) and 310 @entity28 cases (25.7%). The underweight group had a significantly higher rate of poor short and long-term outcomes than the normal weight group. The outcomes of the @entity28 group were not significantly different from those of the normal weight group. Recurrence was not significantly different among the groups. CONCLUSIONS: Lower BMI might be a predictor of poorer short-term and long-term @entity64 outcomes. Geriatr Gerontol Int 2016;       :       -      .

title: Association between body mass index and outcome in Japanese @entity385 XXXX .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity1735 determinants, CCDs) may induce double IgE reactivity to @entity5157 venom ( @entity97 ) and yellow jacket venom (YJV) in @entity1 who are monosensitized to either of these venoms. @entity167 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity97 and YJV) IgE reactivity in @entity1 who are @entity56 to Hymenoptera venom, and in particular, @entity167 consumption. METHODS: Ninety-one @entity1 with Hymenoptera allergy (68 to @entity97 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity97 , YJV, natural (glycosylated) @entity97 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity97 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity97 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity1 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity167 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5157 and @entity58378 ) IgE reactivity are common among Hymenoptera venom- @entity56 @entity1 who drink @entity167 . A simple questionnaire about @entity167 consumption could be useful when interpreting levels of specific IgE in these @entity1 .

title: Double ( @entity5157 and @entity58378 ) immunoglobulin E reactivity in @entity1 XXXX to Hymenoptera venom: the role of cross-reactive carbohydrates and @entity167 consumption.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol', 'Alcohol']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

answer: @entity56 :: (MESH:D004342,Disease) :: ['allergic']


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity1735 determinants, CCDs) may induce double IgE reactivity to @entity5157 venom ( @entity97 ) and yellow jacket venom (YJV) in @entity1 who are monosensitized to either of these venoms. @entity167 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity97 and YJV) IgE reactivity in @entity1 who are @entity56 to Hymenoptera venom, and in particular, @entity167 consumption. METHODS: Ninety-one @entity1 with Hymenoptera allergy (68 to @entity97 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity97 , YJV, natural (glycosylated) @entity97 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity97 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity97 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity1 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity167 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5157 and @entity58378 ) IgE reactivity are common among Hymenoptera venom- @entity56 @entity1 who drink @entity167 . A simple questionnaire about @entity167 consumption could be useful when interpreting levels of specific IgE in these @entity1 .

title: Double ( XXXX and @entity58378 ) immunoglobulin E reactivity in @entity1 @entity56 to Hymenoptera venom: the role of cross-reactive carbohydrates and @entity167 consumption.

answer: @entity5157 :: (7460,Species) :: ['honeybee']


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity1735 determinants, CCDs) may induce double IgE reactivity to @entity5157 venom ( @entity97 ) and yellow jacket venom (YJV) in @entity1 who are monosensitized to either of these venoms. @entity167 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity97 and YJV) IgE reactivity in @entity1 who are @entity56 to Hymenoptera venom, and in particular, @entity167 consumption. METHODS: Ninety-one @entity1 with Hymenoptera allergy (68 to @entity97 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity97 , YJV, natural (glycosylated) @entity97 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity97 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity97 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity1 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity167 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5157 and @entity58378 ) IgE reactivity are common among Hymenoptera venom- @entity56 @entity1 who drink @entity167 . A simple questionnaire about @entity167 consumption could be useful when interpreting levels of specific IgE in these @entity1 .

title: Double ( @entity5157 and @entity58378 ) immunoglobulin E reactivity in @entity1 @entity56 to Hymenoptera venom: the role of cross-reactive carbohydrates and XXXX consumption.

answer: @entity167 :: (CHEBI:16236,Chemical) :: ['alcohol']


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity1735 determinants, CCDs) may induce double IgE reactivity to @entity5157 venom ( @entity97 ) and yellow jacket venom (YJV) in @entity1 who are monosensitized to either of these venoms. @entity167 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity97 and YJV) IgE reactivity in @entity1 who are @entity56 to Hymenoptera venom, and in particular, @entity167 consumption. METHODS: Ninety-one @entity1 with Hymenoptera allergy (68 to @entity97 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity97 , YJV, natural (glycosylated) @entity97 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity97 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity97 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity1 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity167 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5157 and @entity58378 ) IgE reactivity are common among Hymenoptera venom- @entity56 @entity1 who drink @entity167 . A simple questionnaire about @entity167 consumption could be useful when interpreting levels of specific IgE in these @entity1 .

title: Double ( @entity5157 and XXXX ) immunoglobulin E reactivity in @entity1 @entity56 to Hymenoptera venom: the role of cross-reactive carbohydrates and @entity167 consumption.

answer: @entity58378 :: (409218(Tax:7460),Gene) :: ['wasp']


abstract: BACKGROUND: Immunoglobulin (Ig) E-mediated sensitization to N-glycans (cross-reactive @entity1735 determinants, CCDs) may induce double IgE reactivity to @entity5157 venom ( @entity97 ) and yellow jacket venom (YJV) in @entity1 who are monosensitized to either of these venoms. @entity167 consumption is associated with increased IgE levels and possibly with sensitization to CCDs in the general population. OBJECTIVES: This study investigated the factors associated with double ( @entity97 and YJV) IgE reactivity in @entity1 who are @entity56 to Hymenoptera venom, and in particular, @entity167 consumption. METHODS: Ninety-one @entity1 with Hymenoptera allergy (68 to @entity97 , 19 to YJV, and 4 to both venoms) were studied. Determinations included a multiallergen IgE test and IgE to @entity97 , YJV, natural (glycosylated) @entity97 phospholipase-A2 (nPLA2), recombinant (nonglycosylated) @entity97 phospholipase-A2 (rPLA2), MUXF (the N-glycan from bromelain), natural (glycosylated) rubber latex, total IgE. Double reactivity was defined as an IgE level > 0.35 kU(A)/L to @entity97 and YJV. RESULTS: Double reactivity was observed in 28/87 (32%) clinically monosensitized @entity1 . Double reactivity was associated with high levels of total IgE, MUXF-specific IgE, nPLA2-specific IgE, latex-specific IgE, and false-positive results in the multiallergen IgE test, but not with rPLA2-specific IgE. @entity167 consumption was associated with double reactivity and with high levels of IgE to glycosylated allergens after adjusting for confounders in the multivariate analysis. CONCLUSIONS: Sensitization to CCDs and clinically irrelevant double ( @entity5157 and @entity58378 ) IgE reactivity are common among Hymenoptera venom- @entity56 @entity1 who drink @entity167 . A simple questionnaire about @entity167 consumption could be useful when interpreting levels of specific IgE in these @entity1 .

title: Double ( @entity5157 and @entity58378 ) immunoglobulin E reactivity in XXXX @entity56 to Hymenoptera venom: the role of cross-reactive carbohydrates and @entity167 consumption.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Late @entity2287 enhancement (LGE) is widely used to precisely localize and determine the extent and transmurality of @entity296 . Performing LGE imaging at end-systole may reduce motion artefacts. It is therefore important to know whether end-systolic imaging influences infarct transmurality in @entity1 with @entity63 . 107 dysfunctional segments were studied in 20 consecutive @entity1 with established @entity453 . @entity1 specific trigger delays were used to obtain end-diastolic and end-systolic LGE images (LGE(ed), LGE(es)). Wall thickness ( @entity7097 (ed), @entity7097 (es)), thickness of the remaining viable rim (RIM(ed), RIM(es)) and end-diastolic scar thickness were measured manually. There was LGE in 84% of all dysfunctional segments with a mean scar of 3.4    2.5 mm. Total wall thickness and the thickness of the remaining viable rim increased from diastole to systole ( @entity7097 (ed) 7.8    1.9 vs. @entity7097 (es) 8.4    2.2; P < 0.001; RIM(ed) 4.4    3.1 vs. RIM(es) 5    3.4; P < 0.001). Transmurality of scar decreased from end-diastole to end-systole (LGE(ed) 46    33% vs. LGE(es) 44    33%; P < 0.001). This was most pronounced in a subgroup of segments (n = 15) with @entity227 between 50 and 75% (LGE(ed) 75    15% vs. LGE(es) 70    16%; P < 0.001). The change in transmurality was inversely correlated with the change of the thickness of the remaining viable rim between diastole and systole (r = -0.7; P < 0.001). Scar transmurality was reduced by up to 12% in the individual @entity1 . Scar transmurality changes due to thickening of the remaining viable rim. Whereas these differences might not impact on clinical decision-making in most @entity1 , there will be an occasional misclassification if cut-off values are used (e.g. scar <50 or >50%) or if exact data is required for research studies.

title: End-systolic versus end-diastolic late XXXX enhanced imaging for the assessment of scar transmurality.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual scar transmurality']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial scarring']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic scar']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium']

answer: @entity2287 :: (MESH:D005682,Chemical) :: ['gadolinium']


abstract: BACKGROUND AND PURPOSE: To compare psychosocial burden in @entity1 with essential @entity400 (ET) in an outpatient (OPC)- and a community-based cohort (CBC). METHODS: A sample of outpatients of a tertiary referral center (n = 180) and a community-based sample (n = 100) with ET were asked for study participation. Psychosocial aspects were assessed by a questionnaire on psychosocial aspects of ET, neuropsychological scales, quality of life, personality traits, and coping strategies. RESULTS: One hundred and seven @entity1 of the OPC and 90 individuals of the CBC participated and their results are descriptively presented. Statistical analysis was restricted to 38 pairs of OPC and CBC individuals matched for age, sex, and @entity400 severity. One-third of these individuals reported a profound impairment in everyday or professional life. Neuropsychological scales showed a severe @entity308 in 8% of the individuals and pathologic values for the general level of @entity146 symptoms in 26%. The main coping strategy was 'active problem-orientated coping'. @entity1 of the OPC perceived a more severe impact of ET on their life. Multivariate analysis revealed the Beck Depression Inventory score as the only predictive factor for the outcome variables, physical and mental component scores, of the SF-12 health survey. CONCLUSIONS: ET causes a significant @entity73 , which does depend on symptom severity but also on mood with @entity308 as the main driving factor and other so far undetermined factors.

title: The psychosocial burden of essential XXXX in an outpatient- and a community-based cohort.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['psychosocial impairment']

answer: @entity400 :: (MESH:D014202,Disease) :: ['tremor']


abstract: AIM: To estimate the late duration of the effect of 3-week intravenous @entity12837 (alpha-LA) administration. SUBJECTS AND METHODS: The study included @entity1 with symptoms of @entity305 . The authors studied trends in @entity1109 by the TSS scale and @entity51 by the NIS-LL scale after 3-week intravenous alpha-LA (600 mg/day) administration. Control follow-up visits were made at weeks 8 and 30 of the study. RESULTS: In alpha-LA-treated @entity1 , the mean TSS score dropped from 9.46 +/- 1.01 to 3.29 +/- 1.49 after intravenous alpha-LA administration and continued to decrease to 260 +/- 1.18 and 4.39 +/- 201 scores at follow-up weeks 8 and 30, respectively. In the placebo group, these were 9.78 +/- 1.23, 6.16 +/- 1.95, 6.52 +/- 1.61, and 736 +/- 1.31 scores at weeks 3, 8, and 30, respectively; p < 0.05). In the alpha-LA group, NIS-LL scores fell from 8.65 +/- 3.46 to 6.01 +/- 3.12 at therapy week 3, to 6.11 +/- 3.36, at week 8, and to 7.68 +/- 3.68 at week 30 and in the placebo group, these decreased from 8.35 +/- 3.84 to 7.81 +/- 3.51, 7.89 +/- 3.72, and 8.32 +/- 3.49 scores at weeks 3, and 8, respectively; p < 0.05). CONCLUSION: . Alleviated @entity1109 persisted within 6 months after 3-week intravenous alpha-LA injection. Reduced @entity51 did within 8 weeks after initiation of alpha-LA therapy.

title: [Long-term effect of 3-week intravenous XXXX administration in symptomatic diabetic polyneutropathy with clinical manifestations].

entities_list: @entity1109 :: ('MESH:D012678', 'Disease') :: ['neuropathic symptoms']

entities_list: @entity305 :: ('MESH:D011115', 'Disease') :: ['myodiabetic polyneuropathy']

entities_list: @entity12837 :: ('MESH:D008063', 'Chemical') :: ['alpha-lipoic acid']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neuropathic deficit']

answer: @entity12837 :: (MESH:D008063,Chemical) :: ['alpha-lipoic acid']


abstract: BACKGROUND: Modification of allergens by @entity3584 in extracts used for immunotherapy reduces the risk for side effects, but therapeutic efficacy of such extracts requires further evaluation. The aim of this study was to evaluate the efficacy and safety of immunotherapy with PURETHAL Mites (PM), a single-strength @entity3584 -modified @entity13923 -adsorbed extract of @entity6711 ( @entity6711 ). METHODS: In a multicenter, randomized, placebo-controlled double-blind setting, @entity6711 -allergic subjects (n = 140) were treated with modified allergen extract or placebo over a 1-year period. The primary outcome parameter was a combined symptom and medication score (clinical index score [CIS]). Secondary efficacy parameters were the result of a titrated conjunctival provocation test (CPT), @entity2490 / @entity7370 quality of life (RQL) score, and serum concentrations of IgE and IgG against specific @entity6711 allergens and a documentation of adverse events (AE). RESULTS: We evaluated 140 @entity1 (66 treatment and 74 placebo) for clinical efficacy. The allergoid treatment for 1 year resulted in significantly greater CIS improvement and higher RQL scores. The response threshold in the titrated @entity1191 (p = 0.009) and the serum concentrations of IgG4 (p < 0.001) against @entity7130 allergens after treatment were also significantly different between groups. In total, 88 @entity1 (46 PM/42 placebo) out of a safety population of 145 reported 278 (158 PM/120 placebo) AE. Except for local reactions, no specific AE appeared to be associated with PURETHAL Mites (HAL-Allergy, Leiden, The Netherlands). CONCLUSION: The findings of this study indicate that allergen injection therapy with modified @entity6711 extract is superior to placebo in @entity2023 therapy. The treatment was well tolerated and no serious drug-related AE were observed.

title: Efficacy and safety of a XXXX -modified house dust mite extract in @entity2023 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity13923 :: ('MESH:D000536', 'Chemical') :: ['aluminum hydroxide']

entities_list: @entity7370 :: ('OMIM:613207', 'Disease') :: ['rhinoconjunctivitis']

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['allergic rhinitis']

entities_list: @entity7130 :: ('6956', 'Species') :: ['Dermatophagoides pteronyssinus']

entities_list: @entity3584 :: ('MESH:D005976', 'Chemical') :: ['glutaraldehyde']

entities_list: @entity6711 :: ('MESH:D008924', 'Disease') :: ['house-dust mites', 'HDM']

answer: @entity3584 :: (MESH:D005976,Chemical) :: ['glutaraldehyde']


abstract: BACKGROUND: Modification of allergens by @entity3584 in extracts used for immunotherapy reduces the risk for side effects, but therapeutic efficacy of such extracts requires further evaluation. The aim of this study was to evaluate the efficacy and safety of immunotherapy with PURETHAL Mites (PM), a single-strength @entity3584 -modified @entity13923 -adsorbed extract of @entity6711 ( @entity6711 ). METHODS: In a multicenter, randomized, placebo-controlled double-blind setting, @entity6711 -allergic subjects (n = 140) were treated with modified allergen extract or placebo over a 1-year period. The primary outcome parameter was a combined symptom and medication score (clinical index score [CIS]). Secondary efficacy parameters were the result of a titrated conjunctival provocation test (CPT), @entity2490 / @entity7370 quality of life (RQL) score, and serum concentrations of IgE and IgG against specific @entity6711 allergens and a documentation of adverse events (AE). RESULTS: We evaluated 140 @entity1 (66 treatment and 74 placebo) for clinical efficacy. The allergoid treatment for 1 year resulted in significantly greater CIS improvement and higher RQL scores. The response threshold in the titrated @entity1191 (p = 0.009) and the serum concentrations of IgG4 (p < 0.001) against @entity7130 allergens after treatment were also significantly different between groups. In total, 88 @entity1 (46 PM/42 placebo) out of a safety population of 145 reported 278 (158 PM/120 placebo) AE. Except for local reactions, no specific AE appeared to be associated with PURETHAL Mites (HAL-Allergy, Leiden, The Netherlands). CONCLUSION: The findings of this study indicate that allergen injection therapy with modified @entity6711 extract is superior to placebo in @entity2023 therapy. The treatment was well tolerated and no serious drug-related AE were observed.

title: Efficacy and safety of a @entity3584 -modified house dust mite extract in XXXX .

answer: @entity2023 :: (MESH:D006255,Disease) :: ['allergic rhinitis']


abstract: BACKGROUND: Great variability in @entity0 ( @entity0 ) treatment practices according to @entity1 , @entity5 or organisation of care characteristics has been reported but the relation between these factors is not well known. In two French regions, we measured compliance with Clinical Practice Guidelines for non-metastatic @entity0 care management and identified factors associated with non-compliance at clinical and organisational levels. METHODS: Eligible @entity1 had invasive unilateral @entity0 without distant metastases and at least two contacts with one of the two regional healthcare systems (2003-2004) in the first year after diagnosis. Medical data were collected from @entity1 medical records in all public and private hospitals (99 hospitals).The care process was defined by 20 criteria: clinical decisions for treatment and therapeutic procedures. Each criterion was classified according to level of compliance ("Compliant", "Justifiable" and "Not Compliant") and factors of non-compliance were identified (mixed effect logistic regression). RESULTS: 926 @entity1 were included. Non-compliance with clinical decisions for treatment was associated with older @entity1 age (OR 2.1; 95%CI: 1.3-3.6) and region (OR 3.0; 95%CI: 1.2-7.4). Non-compliance with clinical decisions for radiotherapy was associated with lymph node involvement or the presence of peritumoural vascular invasion (OR 1.5; 95%CI: 1.01-2.3) and non-compliance with overall treatment (clinical decisions for treatment + therapeutic procedures) was associated with the presence of positive lymph nodes (OR 2.0; 95%CI: 1.2-3.3), grade III versus grade I (OR 2.9; 95%CI: 1.4-6.2), and one region of care versus another (OR 3.5; 95%CI: 1.7-7.1). Finally, heterogeneity of compliance in overall treatment sequence was identified between @entity5 units (p < 0.05). CONCLUSION: This study provides interesting insights into factors of non-compliance in non-metastatic @entity0 management and could lead to quality care improvements.

title: XXXX care compared with clinical Guidelines: an observational study in France.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['local cancer', 'tumour']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'BC']

answer: @entity0 :: (MESH:D001943,Disease) :: ['Breast cancer']


abstract: INTRODUCTION: Cardiac @entity3 are found in six to 20% of autopsies of @entity1 with @entity5 . The most common @entity5 that metastasize to the heart are @entity320 , and @entity1778 , but the relative numbers are greater with @entity0 , reflecting the most common incidence of these @entity5 . CASE PRESENTATION: A 60-year-old Hispanic @entity1 presented to our hospital after being transferred from an outside hospital for workup and evaluation of an adrenal mass of the abdomen and pelvis, found on computed tomography. His chief complaint upon admission was altered mental status. Physical examination was unremarkable. He was alert and oriented and had a dry and non-erythematous oropharynx, and bilateral diffuse wheezing on lung examination. Computed tomography of the chest showed @entity75 in the left ventricular myocardium, suggestive of @entity3 . There were also tiny sub-centimeter nodular densities in the right upper and lower lobes. Adrenal glands contained @entity75 , which showed characteristic adenocarcinomatous malignant cells. CONCLUSION: @entity5 which have metastasized to the heart are found in six to 20% of @entity1 with @entity5 . The right side of the heart is more commonly involved in @entity3 . This study is unusual in that a @entity5 of an unknown primary origin had metastasized to the left side of the heart.

title: An unusual case of XXXX to the left side of the heart: a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'man']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast and lung cancers']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancers', 'cancers', 'malignant neoplasms', 'neoplasms', 'malignant neoplasm']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['multiple hypodense lesions', 'hypodense lesions']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['malignant melanoma, lymphoma']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastasis']


abstract: Previous studies have demonstrated a correlation between E:E(a) and ventricular filling pressure in adults after heart transplantation. We sought to determine if E:E(a) correlates with filling pressure after heart transplantation in chil @entity1 prospective analysis of chil @entity1 have undergone heart transplantation was performed. Inflow and myocardial velocities were recorded and compared to catheter-derived filling pressures and rejection status. We performed 61 studies in 49 subjects. No correlation was found between septal E:E(a) and PCWP (r=0.14, p=0.28); or between lateral tricuspid E:E(a) and mean RAp @entity541 0.04, p=0.79). However, the mean PCWP was higher among subjects with elevated septal E:E(a) (>12) compared to normal E:E(a) (12.3  2.8mmHg vs. 10.1  2.9mmHg, p=0.02). Similarly, mean RAp @entity541 higher among subjects with an elevated lateral tricuspid E:E(a) (>10) compared to normal lateral tricuspid E:E(a) (7.7  2.1mmHg vs. 6.0  2.4mmHg, p=0.04). Elevated septal E:E(a) was also associated with high-grade cellular rejection (OR=17.3 [95% CI 1.4-221], p=0.028). In chil @entity1 lowing heart transplant, E:E(a) does not correlate well with the range of filling pressures seen after pediatric heart transplantation. However, a septal E:E(a)>12 is associated with elevated PCWP and high grade cellular rejection and a lateral tricuspid E:E(a)>10 is associated with elevated mean RAp. @entity541

title: Doppler tissue imaging in XXXX following cardiac transplantation: a comparison to catheter derived hemodynamics.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: We tested the acceptability of three new lipid-based nutrient supplements (LNSs) in two independent phases among 18 8-12-month-old healthy rural Malawians and their caregivers. In phase 1, acceptability was assessed by offering three new LNSs in random order, and an @entity24901 already determined to be acceptable, Nutributter(  ), each added to 30 g of warm @entity2829 porridge over three consecutive days. In phase 2, @entity1 from each village were provided one of the new supplements for a 2-week home-use trial. Outcome measures included the amount consumed, time completion of the dose and the maternal rating of likeability on a 5-point scale. The supplements were rated acceptable if consumption was over 50% of the offered dose in phase 1. The mean (95% confidence interval) proportion of the @entity24901 test meals consumed under direct observation was 88% (82-94%) for @entity24901 -10gM, 90% (84-95%) for @entity24901 -20gM, 87% (79-95%) for @entity24901 -20gNoM, and 86% (83-90%) for Nutributter. The median (25th and 75th centile) time (minutes) for completing the offered test meal was 4 (2, 7) for @entity24901 -10gM, 5 (3, 6) for @entity24901 -20gM, 4 (3, 8) for @entity24901 -20gNoM and 4 (2, 6) for Nutributter. During both phases, almost all caregivers rated all study foods very likeable for themselves and their @entity1 , with mean scores slightly lower among the caregivers than among the @entity1 . In the home-use phase, the test foods were almost exclusively used by the study @entity1 with minimal sharing with siblings and other household members. Some @entity1 were reported to prefer the new investigational products over traditional complementary food. Considering that the novel @entity24901 was largely acceptable. Efficacy trials are now needed to assess their impact on @entity1 growth and development.

title: Acceptability of three novel lipid-based nutrient supplements among Malawian XXXX and their caregivers.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'child', 'children', 'infants']

answer: @entity1 :: (9606,Species) :: ['infants']


abstract: AIM: The aim of the study was to evaluate the prevalence and risk factors of @entity74 among Polish adolescent @entity1 . MATERIAL AND METHODS: A total of 2500 females from the Upper Silesian region of Poland, aged 16 to 45 years, were eligible for a prospective population-based study. The subjects were recruited randomly by the regional public opinion research centre. The preliminary study population consisted of 1540 females. Seventy-two adolescent @entity1 , aged 16 to 19 years, were included in the final analysis. The research was based on a self-prepared questionnaire containing socio-economic status, general health, medical and reproductive history, @entity1109 based on American College of Obstetricians and Gynecologists criteria for diagnosing @entity3010 as well as American Psychiatric Association criteria for @entity14052 and @entity1 prospective daily ratings of symptoms. RESULTS: The mean age of the studied population was 17.27  0.97 years. In the studied population the majority of the adolescent @entity1 lived in large cities of over 50,000 citizens (54.29%), were physically active declaring daily physical exercise (55.22%) and sexually active (54.17%). Study results indicated that the prevalence of @entity3010 and @entity14052 was 76.39% and 4.17%, respectively. The final statistical analysis revealed that only place of residence (large cities) increased the risk of @entity3010 (OR=3.58; P=0.01). CONCLUSION: Adolescent females living in urban areas are more vulnerable to @entity3010 . Reproductive, sexual and socio-economic factors are not significant risk factors for @entity3010 .

title: XXXX in Polish adolescent @entity1 : prevalence and risk factors.

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'girls']

entities_list: @entity14052 :: ('MESH:D065446', 'Disease') :: ['premenstrual dysphoric disorder']

entities_list: @entity1109 :: ('MESH:D012678', 'Disease') :: ['premenstrual symptoms']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['premenstrual disorders']

entities_list: @entity3010 :: ('MESH:D011293', 'Disease') :: ['premenstrual syndrome']

answer: @entity74 :: (MESH:D030342,Disease) :: ['Premenstrual disorders']


abstract: AIM: The aim of the study was to evaluate the prevalence and risk factors of @entity74 among Polish adolescent @entity1 . MATERIAL AND METHODS: A total of 2500 females from the Upper Silesian region of Poland, aged 16 to 45 years, were eligible for a prospective population-based study. The subjects were recruited randomly by the regional public opinion research centre. The preliminary study population consisted of 1540 females. Seventy-two adolescent @entity1 , aged 16 to 19 years, were included in the final analysis. The research was based on a self-prepared questionnaire containing socio-economic status, general health, medical and reproductive history, @entity1109 based on American College of Obstetricians and Gynecologists criteria for diagnosing @entity3010 as well as American Psychiatric Association criteria for @entity14052 and @entity1 prospective daily ratings of symptoms. RESULTS: The mean age of the studied population was 17.27  0.97 years. In the studied population the majority of the adolescent @entity1 lived in large cities of over 50,000 citizens (54.29%), were physically active declaring daily physical exercise (55.22%) and sexually active (54.17%). Study results indicated that the prevalence of @entity3010 and @entity14052 was 76.39% and 4.17%, respectively. The final statistical analysis revealed that only place of residence (large cities) increased the risk of @entity3010 (OR=3.58; P=0.01). CONCLUSION: Adolescent females living in urban areas are more vulnerable to @entity3010 . Reproductive, sexual and socio-economic factors are not significant risk factors for @entity3010 .

title: @entity74 in Polish adolescent XXXX : prevalence and risk factors.

answer: @entity1 :: (9606,Species) :: ['girls']


abstract: BACKGROUND: @entity3 ( @entity3 ) has become the procedure of choice in the treatment of @entity459 where a single @entity652 can be localized preoperatively. The role for intra-operative @entity461 measurement (IOPTH) is controversial. Some experts recommend that IOPTH is a mandatory requirement for successful @entity3 while others state that the technique is not needed. We reviewed 10 years of @entity3 in a single unit without the use of IOPTH in order to examine causes of failure. METHODS: This study is a retrospective review of the University of Sydney Endocrine Surgery Database from May of 1998 to August of 2008. The database was queried for MIPs performed as well as for failed operations. @entity1 record analysis was completed to determine the reason for failure of the operation. RESULTS: In the period January 1998 to August 2008, a total of 2343 parathyroidectomy procedures were performed. Of these, 1020 were MIPs with 23 (2.2%) failures. One @entity1 was found to have benign familial @entity2741 , whereas five were lost to follow-up. Reasons for failure in the remaining 17 @entity1 were: 10 @entity1 (59%) were found to have double @entity652 , 3 (17%) @entity1 with @entity1373 and 4 (24%) @entity1 with single gland disease were missed at initial operation. All 17 were cured on repeat exploration. CONCLUSION: @entity3 can be performed safely and with 98% success without the need for IOPTH. The most common cause of failure after @entity3 is an occult double @entity652 . Given that repeat sestamibi scan correctly identifies persistent disease in most cases, consideration can be given to @entity3 as a choice of procedure for repeat operation.

title: 1000 minimally invasive parathyroidectomies without intra-operative XXXX measurement: lessons learned.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity459 :: ('MESH:D049950', 'Disease') :: ['primary hyperparathyroidism']

entities_list: @entity2741 :: ('MESH:D006934', 'Disease') :: ['hypercalcemia']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['MIP', 'Minimally invasive parathyroidectomy']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'adenoma']

entities_list: @entity461 :: ('5741', 'Gene') :: ['parathyroid hormone']

answer: @entity461 :: (5741,Gene) :: ['parathyroid hormone']


abstract: BACKGROUND: Available drug-eluting stents (DES) have achieved great success in reducing restenosis rates. Recently, investigators have demonstrated that the durable polymer carrier plays a significant role in DES-related hypersensitive reaction and delays vessel healing. TIVOLI stent is a novel @entity3446 -eluting coronary stent with biodegradable coating containing @entity3446 and @entity7050 ( @entity7050 ) polymer. The present study sought to evaluate the effectiveness and safety of the TIVOLI biodegradable-polymer-based @entity3446 -eluting stent in treating @entity1 with @entity453 . METHODS: A prospective, multicenter clinical trial comparing TIVOLI biodegradable coated @entity3446 -eluting stent with ENDEAVOR zotarolimus-eluting stent was conducted in 324 @entity1 (TIVOLI group: 168 @entity1 ; ENDEAVOR group: 156 @entity1 ) at 12 centers in China to demonstrate the non-inferiority of in-stent late loss with TIVOLI stent compared to ENDEAVOR stent in subjects with a maximum of two de novo native @entity453 (lesion length  <= 40 mm, reference vessel diameter 2.25-4.00 mm). The primary end point was angiographic in-stent late loss at 8-month. The secondary end points were clinical outcomes at 2 years, including major adverse @entity299 ( @entity204 , @entity583 , or @entity75 revascularization) and stent @entity715 . RESULTS: Angiographic late lumen loss at 8 months in the TIVOLI group was superior to the ENDEAVOR group (in-stent (0.25    0.33) mm vs. (0.57    0.55) mm, diff (95%CI) -0.23 (-0.32, -0.14), P < 0.0001; in-segment (0.25    0.33) mm vs. (0.42    0.55) mm, diff (95%CI) -0.13 (-0.23, -0.02), P = 0.0083). The rate of in-stent binary restenosis at 8 months was reduced from 8.6% in the ENDEAVOR group to 2.9% in the TIVOLI group (P = 0.0229). Compared to ENDEAVOR stent, TIVOLI stent resulted in a significant reduction in @entity75 revascularization (4.2% vs. 9.6%, P = 0.0495) at 2 years. The two-year major adverse @entity299 (MACE) rate was lower for the TIVOLI group, but not significantly different (6.6% vs. 10.9%, P = 0.1630). CONCLUSIONS: TIVOLI was superior to ENDEAVOR stent with respect to late lumen loss at 8 months, and it yielded both lower rates of @entity256 at 8 months and @entity75 revascularization (TLR) at 2 years. The MACE rate at 2 years was comparable in both groups.

title: A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based XXXX -eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of @entity453 : 8-month angiographic and 2-year clinical follow-up results.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['target-lesion', 'target lesion']

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['angiographic binary restenosis']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus']

entities_list: @entity7050 :: ('MESH:C043435', 'Chemical') :: ['polylactic-co-glycolic acid', 'PLGA']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery lesions', 'coronary artery disease']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity3446 :: (MESH:D020123,Chemical) :: ['sirolimus']


abstract: BACKGROUND: Available drug-eluting stents (DES) have achieved great success in reducing restenosis rates. Recently, investigators have demonstrated that the durable polymer carrier plays a significant role in DES-related hypersensitive reaction and delays vessel healing. TIVOLI stent is a novel @entity3446 -eluting coronary stent with biodegradable coating containing @entity3446 and @entity7050 ( @entity7050 ) polymer. The present study sought to evaluate the effectiveness and safety of the TIVOLI biodegradable-polymer-based @entity3446 -eluting stent in treating @entity1 with @entity453 . METHODS: A prospective, multicenter clinical trial comparing TIVOLI biodegradable coated @entity3446 -eluting stent with ENDEAVOR zotarolimus-eluting stent was conducted in 324 @entity1 (TIVOLI group: 168 @entity1 ; ENDEAVOR group: 156 @entity1 ) at 12 centers in China to demonstrate the non-inferiority of in-stent late loss with TIVOLI stent compared to ENDEAVOR stent in subjects with a maximum of two de novo native @entity453 (lesion length  <= 40 mm, reference vessel diameter 2.25-4.00 mm). The primary end point was angiographic in-stent late loss at 8-month. The secondary end points were clinical outcomes at 2 years, including major adverse @entity299 ( @entity204 , @entity583 , or @entity75 revascularization) and stent @entity715 . RESULTS: Angiographic late lumen loss at 8 months in the TIVOLI group was superior to the ENDEAVOR group (in-stent (0.25    0.33) mm vs. (0.57    0.55) mm, diff (95%CI) -0.23 (-0.32, -0.14), P < 0.0001; in-segment (0.25    0.33) mm vs. (0.42    0.55) mm, diff (95%CI) -0.13 (-0.23, -0.02), P = 0.0083). The rate of in-stent binary restenosis at 8 months was reduced from 8.6% in the ENDEAVOR group to 2.9% in the TIVOLI group (P = 0.0229). Compared to ENDEAVOR stent, TIVOLI stent resulted in a significant reduction in @entity75 revascularization (4.2% vs. 9.6%, P = 0.0495) at 2 years. The two-year major adverse @entity299 (MACE) rate was lower for the TIVOLI group, but not significantly different (6.6% vs. 10.9%, P = 0.1630). CONCLUSIONS: TIVOLI was superior to ENDEAVOR stent with respect to late lumen loss at 8 months, and it yielded both lower rates of @entity256 at 8 months and @entity75 revascularization (TLR) at 2 years. The MACE rate at 2 years was comparable in both groups.

title: A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based @entity3446 -eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of XXXX : 8-month angiographic and 2-year clinical follow-up results.

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary artery disease']


abstract: INTRODUCTION: @entity8267 is a major cause of lobar @entity548 in older adults, and of microvascular @entity63 . The rarest form of this disease is an inflammatory form causing @entity410 . It is important to recognize because the @entity1 usually respond to a brief course of immunosuppression. METHODS: Case report. RESULTS: A 66-year-old @entity1 developed gradual @entity73 , insidiously increasing headaches, and then had a likely @entity410 . MRI showed @entity4 , and innumerable superficial microhemorrhages characteristic of @entity2333 . He was empirically treated with oral @entity229 and an anticonvulsant. His symptoms improved and the white matter @entity4 resolved over several months. @entity2204 genotype was 4/4, which is commonly found in inflammatory @entity2333 . CONCLUSIONS: Inflammatory @entity8267 can be clinically diagnosed and treated without brain biopsy. Clinical diagnosis is important because of the good response to a brief course of @entity230 in most cases.

title: Clinical diagnosis and successful treatment of inflammatory XXXX .

entities_list: @entity8267 :: ('MESH:D016657', 'Disease') :: ['cerebral amyloid angiopathy', 'Cerebral amyloid angiopathy']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'man']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic disease']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive decline']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['edema', 'diffuse white matter edema']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity2333 :: ('MESH:D001018', 'Disease') :: ['amyloid angiopathy']

answer: @entity8267 :: (MESH:D016657,Disease) :: ['cerebral amyloid angiopathy']


abstract: BACKGROUND: A study was undertaken to evaluate results of surgery and radiotherapy (RT) for high-risk extracranial @entity511 . METHODS: Between 1986 and 2006, 60 @entity1 underwent surgery and RT for @entity853 . Preoperative RT (median, 50 gray [Gy]) and postoperative RT (median, 60 Gy) were used in 40% and 60% @entity1 , respectively. Sites included pelvis/lower extremity (48%), chest wall (22%), spine/paraspinal (17%), and head and neck (13%). Overall, median @entity5 size was 7 cm (range, 1-22 cm), and @entity5 grade was I, II, and III in 22%, 64%, and 14% of cases, respectively. RESULTS: Pathologically clear surgical margins (R0) were present in 50%, microscopic positive margins (R1) in 28%, and gross positive margins (R2) in 13%, half of whom had clinically detectable residual disease; surgical margin was unknown in 8%. Median follow-up was 75 months (range, 5-230 months). The crude local control rate was 90%. @entity1 with R0, R1, and R2 resections had local control of 100%, 94%, and 42%, respectively. Of the 8 cases that had R2 resection, 3 experienced uncontrolled progression, but 5 @entity1 had stable disease with long-term follow-up. The 10-year overall survival, progression-free survival, and cause-specific survival were 86%, 80.5%, and 89.4%, respectively. Younger age and @entity5 were associated with worse progression-free survival (P = .03 and .0003, respectively). CONCLUSIONS: Although surgery with complete resection is paramount in management of @entity511 , RT is a useful adjuvant treatment and appears to offer excellent and durable local control where wide surgical resection is difficult to accomplish.

title: High-risk extracranial XXXX : long-term results of surgery and radiation therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity511 :: ('MESH:D002813', 'Disease') :: ['chondrosarcoma', 'chondrosarcomas']

entities_list: @entity853 :: ('MESH:D009139', 'Disease') :: ['extracranial high-risk chondrosarcoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'grade III tumors']

answer: @entity511 :: (MESH:D002813,Disease) :: ['chondrosarcoma']


abstract: PURPOSE: The aim of this study was to determine the incidence of winged scapula after @entity0 surgery, its impact on shoulder morbidity and difference in incidence according to surgery type. METHODS: @entity1 with @entity0 and surgical indication for axillary dissection were included. A total of 112 @entity1 were surveyed with one physical evaluation before the surgery and others 15, 30, 90, and 180  days after. Winged scapula was assessed with test proposed by Hoppenfeld. Shoulder range of motion (ROM) was assessed with goniometer for flexion, extension, adduction, abduction, internal rotation, and external rotation. A verbal scale from 0 to 10 was used to assess @entity158 . RESULTS: Winged scapula incidence was 8.0  % 15  days after surgery. Two @entity1 recovered from winged scapula 90  days after surgery and four more 180  days after surgery, while three @entity1 still had winged scapula at this time. The incidence after 15  days from surgery was 20.9 and 22.6  % among @entity1 submitted to sentinel node biopsy or axillary lymphadenectomy (AL), respectively (p   <   0.01). There was no statistical difference of incidence according to breast surgery type. Operated side shoulder flexion, adduction, and abduction ROM changes were statistically different in @entity1 with or without winged scapula. The mean reduction was higher in @entity1 with winged scapula. Both groups showed the same pattern over time in @entity158 . CONCLUSION: Winged scapula incidence was 8.0  % and was higher in AL, and prevalence decreased during 6  months after surgery. @entity1 who developed winged scapula had more shoulder flexion, adduction, and abduction limitation.

title: Winged scapula incidence and upper limb morbidity after surgery for XXXX with axillary dissection.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: UNASSIGNED: We assessed the effect of single and repeated doses of bevacizumab, ranibizumab, and aflibercept on cell viability, proliferation, permeability, and apoptosis of @entity1 cells. @entity98 and @entity1603 assays were used to determine viability and proliferation after single or repeated doses of anti- @entity7 drugs under normal and oxidative stress conditions. @entity522 expression after single and repeated doses of the 3 drugs was assessed using immunofluorescence. Transepithelial-electrical-resistance (TER) was measured to study the effect of anti-VEGFs on @entity989 ( @entity989 ) permeability under normal and oxidative stress conditions. Flow cytometry was used to detect intracellular accumulation of the drugs. Finally, a wound healing assay was performed to investigate the effect of the drugs on @entity989 cell migration. Single and multiple doses of anti- @entity7 drugs had no effect on cell viability and proliferation. The oxidative effect of @entity5568 decreased cell viability and proliferation; however, no difference was observed between anti- @entity7 treatments. Immunofluorescence performed after single and repeated doses of the drugs revealed some @entity522 expression. Interestingly, anti-VEGFs restored the increased permeability induced by @entity5568 . The 3 drugs accumulated inside the cells and were detectable 5days after treatment. Finally, none of the drugs affected migration. In conclusion, no measureable @entity137 effect was observed after single or repeated doses of @entity7 antagonists under normal and oxidative stress. Intracellular accumulation of the drugs does not seem to be @entity137 or affect cell functions. Our study suggests that anti-VEGFs could have a preventive effect on the maintenance of the @entity989 barrier under oxidative stress.

title: Single- and repeated-dose XXXX study of bevacizumab, ranibizumab, and aflibercept in @entity1 cells under normal and oxidative stress conditions.

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinal pigment epithelium', 'RPE']

answer: @entity137 :: (MESH:D064420,Disease) :: ['toxicity']


abstract: UNASSIGNED: We assessed the effect of single and repeated doses of bevacizumab, ranibizumab, and aflibercept on cell viability, proliferation, permeability, and apoptosis of @entity1 cells. @entity98 and @entity1603 assays were used to determine viability and proliferation after single or repeated doses of anti- @entity7 drugs under normal and oxidative stress conditions. @entity522 expression after single and repeated doses of the 3 drugs was assessed using immunofluorescence. Transepithelial-electrical-resistance (TER) was measured to study the effect of anti-VEGFs on @entity989 ( @entity989 ) permeability under normal and oxidative stress conditions. Flow cytometry was used to detect intracellular accumulation of the drugs. Finally, a wound healing assay was performed to investigate the effect of the drugs on @entity989 cell migration. Single and multiple doses of anti- @entity7 drugs had no effect on cell viability and proliferation. The oxidative effect of @entity5568 decreased cell viability and proliferation; however, no difference was observed between anti- @entity7 treatments. Immunofluorescence performed after single and repeated doses of the drugs revealed some @entity522 expression. Interestingly, anti-VEGFs restored the increased permeability induced by @entity5568 . The 3 drugs accumulated inside the cells and were detectable 5days after treatment. Finally, none of the drugs affected migration. In conclusion, no measureable @entity137 effect was observed after single or repeated doses of @entity7 antagonists under normal and oxidative stress. Intracellular accumulation of the drugs does not seem to be @entity137 or affect cell functions. Our study suggests that anti-VEGFs could have a preventive effect on the maintenance of the @entity989 barrier under oxidative stress.

title: Single- and repeated-dose @entity137 study of bevacizumab, ranibizumab, and aflibercept in XXXX cells under normal and oxidative stress conditions.

answer: @entity1 :: (9606,Species) :: ['ARPE-19']


abstract: Accumulating evidence indicates a decisive role for the adjacent stroma in @entity5 growth and dissemination. However, it is not clear how far altered differentiation such as expression of aberrant keratins and @entity2277 , common in invasive @entity1 @entity189 , may reflect intrinsic cell properties or a response to the @entity5 environment. We have addressed this by transplanting benign and malignant @entity1 HaCaT-ras keratinocytes, seeded on collagen matrix, onto @entity19 . Initially, epithelia derived from benign and malignant cells, being separated from host stroma by collagen, were poorly organized and exhibited the same differentiation markers, as identified by immunofluorescence and in situ hybridization. Epidermal basal and suprabasal keratins were expressed persistently even upon contact with newly formed stroma and malignant cell invasion. In contrast, non-epidermal keratins (K4/ @entity7435 , K8/18, @entity4166 ), which were similarly synthesized by benign and malignant cells in culture and in early transplants, were differentially regulated with increasing stromal vicinity. While both proteins and mRNAs were downregulated in benign epithelia, the malignant, invasive @entity5 cells continuously expressed these non-epidermal keratins throughout ( @entity4166 ), suprabasally ( @entity218 ) or at invasive sites (K8/18). Furthermore, the mesenchymal protein @entity2277 was expressed de novo in invasive areas confronting @entity5 stroma. Thus, atypical tissue markers, similarly synthesized in isolated cells in vitro, are downregulated in benign but maintained and upregulated in malignant epithelia. This is presumably caused by the neighbouring stroma being permanently activated by malignant epithelia.

title: Discriminating expression of differentiation markers evolves in transplants of benign and malignant XXXX skin keratinocytes through stromal interactions.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVES: This study aims to investigate the possible relationship between smoking and @entity14696 in smokers, non-smokers and ex-smokers. @entity1 AND METHODS: Between March 01st, 2014 and March 31st, 2014, a total of 1,840 @entity1 (823 males, 1,017 females) over 25 years of age who were admitted to the ear nose, and throat (ENT) outpatient clinic were included in the study. The @entity1 who were smoking at least 10 cigarettes daily for at least five years were included in the smokers group (n=514). The @entity1 who did not smoke for at least one year following at least five years of smoking were included in the ex-smokers group (n=268). The @entity1 who never smoked were included in the non-smokers group (n=1,058). A form containing all ENT symptoms was given to all @entity1 and the @entity1 were asked to fill the form with their complaints following being informed by the same doctor. RESULTS: Cough, @entity1353 , reflux, dryness of throat, irritation, @entity1702 , bad breath, toothache, nasal congestion, @entity4838 , snoring, and nasal discharge were found to be significantly higher in the smokers group, compared to the non-smokers group. Cough, sputum, hoarseness, @entity1282 , reflux, sore throat, dryness of throat, irritation, stinging, oral aphthae, @entity1702 , toothache, @entity548 gums, and bad breath were significantly lower in the ex-smokers group. Nasal congestion, nosebleeds, sneezing, nasal discharge, @entity4838 , @entity10 , feeling of facial @entity27915 , @entity2169 , @entity393 , @entity158 , @entity27915 , @entity1296 , and @entity392 were statistically significantly lower in the ex-smokers group. CONCLUSION: Our study results show that smoking causes symptoms particularly associated with upper respiratory tract and these symptoms may persist in ex-smokers.

title: Relationship between smoking and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity1353 :: ('MESH:D004417', 'Disease') :: ['shortness of breath']

entities_list: @entity1702 :: ('MESH:D013651', 'Disease') :: ['taste disorder']

entities_list: @entity14696 :: ('MESH:D010038', 'Disease') :: ['otorhinolaryngological symptoms']

entities_list: @entity392 :: ('MESH:D014012', 'Disease') :: ['tinnitus']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']

entities_list: @entity4838 :: ('MESH:D000857', 'Disease') :: ['smell disorders']

entities_list: @entity2169 :: ('MESH:D004427', 'Disease') :: ['ear discharge']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity14696 :: (MESH:D010038,Disease) :: ['otorhinolaryngological symptoms']


abstract: BACKGROUND/AIMS: The aim of this study was to report results of @entity5273 ( @entity5273 ) in 5 consecutive @entity1 with cystic @entity82 and monitor long-term follow-up results. METHODOLOGY: Five cystic @entity82 @entity1 with multinodular @entity1575 and complications of portal @entity101 (repeated variceal @entity548 refractory to endoscopic treatment) underwent @entity5273 creation. There were 3 males and 2 females aged 8 to 18 years (median 14 yrs), their weight range was 27-51 (median 40) kg. A routine @entity5273 technique was used. The @entity1 were followed by ultrasonography. RESULTS: The @entity5273 was successfully performed in all five @entity1 . The mean portosystemic pressure gradient was reduced from 17 to 10 mmHg. There were no deaths related to the procedure. No clinical or laboratory signs of @entity548 into the gastrointestinal tract were observed in any @entity1 within the first 30 days following @entity5273 . There was recurrent @entity548 6 times and asymptomatic stenoses were revealed by ultrasonography 15 times during a follow-up period of 15-81 (median 70) months. All stenoses were successfully dilated. One @entity1 had liver transplantation 15 months after @entity5273 . Two @entity1 died 6.7 years and 4.5 years following the placement of @entity5273 due to @entity1576 . CONCLUSIONS: Symptomatic portal @entity101 was successfully managed with @entity5273 in long-term follow-up; multiple reinterventions were required for shunt stenoses. @entity5273 served as a bridge to liver transplantation in one case.

title: Transjugular intrahepatic portosystemic shunt in five @entity1 with cystic XXXX : long-term results.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity5273 :: ('MESH:C562830', 'Disease') :: ['TIPS', 'transjugular intrahepatic portosystemic shunt']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory insufficiency']

entities_list: @entity1575 :: ('MESH:D008103', 'Disease') :: ['cirrhosis of the liver']

answer: @entity82 :: (MESH:D005355,Disease) :: ['fibrosis']


abstract: BACKGROUND/AIMS: The aim of this study was to report results of @entity5273 ( @entity5273 ) in 5 consecutive @entity1 with cystic @entity82 and monitor long-term follow-up results. METHODOLOGY: Five cystic @entity82 @entity1 with multinodular @entity1575 and complications of portal @entity101 (repeated variceal @entity548 refractory to endoscopic treatment) underwent @entity5273 creation. There were 3 males and 2 females aged 8 to 18 years (median 14 yrs), their weight range was 27-51 (median 40) kg. A routine @entity5273 technique was used. The @entity1 were followed by ultrasonography. RESULTS: The @entity5273 was successfully performed in all five @entity1 . The mean portosystemic pressure gradient was reduced from 17 to 10 mmHg. There were no deaths related to the procedure. No clinical or laboratory signs of @entity548 into the gastrointestinal tract were observed in any @entity1 within the first 30 days following @entity5273 . There was recurrent @entity548 6 times and asymptomatic stenoses were revealed by ultrasonography 15 times during a follow-up period of 15-81 (median 70) months. All stenoses were successfully dilated. One @entity1 had liver transplantation 15 months after @entity5273 . Two @entity1 died 6.7 years and 4.5 years following the placement of @entity5273 due to @entity1576 . CONCLUSIONS: Symptomatic portal @entity101 was successfully managed with @entity5273 in long-term follow-up; multiple reinterventions were required for shunt stenoses. @entity5273 served as a bridge to liver transplantation in one case.

title: Transjugular intrahepatic portosystemic shunt in five XXXX with cystic @entity82 : long-term results.

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND AND OBJECTIVE: We recently developed a new population pharmacokinetic model for @entity10748 in @entity1 including age and bodyweight as covariates. The aim of the present study was to evaluate prospectively the predictive performance of this new model during @entity282 therapy. METHODS: This was a prospective, single-blinded, randomized, single-center study with two parallel arms. Fifty @entity1 aged 40-85  years undergoing cardiac surgery involving thoracotomy were enrolled. @entity10748 was administered postoperatively on the intensive care unit as target controlled infusion (TCI) for @entity1 controlled analgesia (TCI-PCA) using the new pharmacokinetic model, or as conventional @entity1 controlled analgesia (PCA). Arterial blood samples were taken for measurement of the @entity10748 plasma concentration. The predictive performance of the pharmacokinetic model was assessed by the @entity2246 ( @entity2246 ), the median absolute performance error (MDAPE), wobble and divergence. For comparison, the performance indices were also determined for three older models from the literature. RESULTS: 903 plasma concentrations of 41 @entity1 were analyzed. The mean values (95  % CI) of @entity2246 , MDAPE, wobble and divergence for the new pharmacokinetic model were 11.2  % (3.9 to 18.7  %), 28.5  % (23.9 to 33.0  %), 21.4  % (18.0 to 24.9  %) and -1.6  %/h (-2.3 to -0.8  %/h). When compared with older models from the literature, performance was better with less overshoot after bolus doses. CONCLUSION: The new pharmacokinetic model of @entity10748 showed a good precision and a better performance than older models. It is therefore suitable for TCI with @entity10748 during @entity282 therapy. TRIAL REGISTRATION: EudraCT 2013-002875-16, Clinical Trials NCT02035709.

title: External Validation of a Recently Developed Population Pharmacokinetic Model for XXXX During Postoperative Pain Therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

entities_list: @entity10748 :: ('MESH:D004091', 'Chemical') :: ['hydromorphone', 'Hydromorphone']

entities_list: @entity2246 :: ('MESH:D008661', 'Disease') :: ['median performance error', 'MDPE']

answer: @entity10748 :: (MESH:D004091,Chemical) :: ['Hydromorphone']


abstract: UNASSIGNED: A cellulase-producing bacterium isolated from pulp and paper feedstock, Bacillus sp. AR03, was evaluated by means of a factorial design showing that peptone and @entity3363 were the main variables affecting enzyme production. Simple @entity3363 , individually and combined with @entity5070 cellulose (CMC), were further examined for their influence on cellulase production by strain AR03. Most of the mono and @entity7967 assayed presented a synergistic effect with CMC. As a result, a peptone-based broth supplemented with 10  g/L @entity969 and 10  g/L CMC maximized enzyme production after 96  h of cultivation. This medium was used to produce endoglucanases in a 1-L stirred tank reactor in batch mode at 30    C, which reduced the fermentation period to 48  h and reaching 3.12        0.02  IU/mL of enzyme activity. Bacillus sp. AR03 endoglucanases showed an optimum temperature of 60    C and a pH of 6.0 with a wide range of pH stability. Furthermore, presence of 10  mM @entity3281 and 5  mM @entity3158 produced an increase of enzyme activity (246.7 and 183.7  %, respectively), and remarkable tolerance to @entity4202 , @entity9266 , and @entity1098 was also observed. According to our results, the properties of the cellulolytic cocktail from Bacillus sp. AR03 offer promising features in view of potential biorefinery applications.

title: Synergistic Effect of Simple Sugars and XXXX Cellulose on the Production of a Cellulolytic Cocktail from Bacillus sp. AR03 and Enzyme Activity Characterization.

entities_list: @entity7967 :: ('MESH:D004187', 'Chemical') :: ['disaccharides']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity5070 :: ('CHEBI:41402', 'Chemical') :: ['carboxymethyl']

entities_list: @entity3363 :: ('MESH:D002241', 'Chemical') :: ['sugars', 'carbohydrates']

answer: @entity5070 :: (CHEBI:41402,Chemical) :: ['Carboxymethyl']


abstract: The objective of this article is to describe the range of orthopaedic injuries and outcomes of acute treatment regimens among survivors of the USS COLE terrorist attack and to reemphasize basic treatment principles for @entity3614 . With the current geopolitical environment, the average community orthopaedic surgeon may be involved in treating injuries due to an explosive terrorist attack. This is a retrospective review of a consecutive series of the 39 @entity1 who were injured during the USS COLE attack on October 12, 2000, and were received at Naval Medical Center, Portsmouth, Virginia, from the MEDEVAC (Medical Evacuation) system. The 17 casualties from the attack were not included in this study. Data were retrospectively collected from @entity1 charts for all @entity1 who survived the USS COLE attack. The 39 @entity1 who survived the USS COLE attack sustained 81 injuries. Fourteen @entity1 sustained 32 orthopaedic injuries, of which 61% were lower extremity injuries. Of the 10 @entity1 who required hospitalization, 6 had orthopaedic injuries (60%). Three of five @entity4422 (60%) became infected, and two of two (100%) open @entity174 wounds treated with primary closure in the initial setting were infected. Lower @entity130 may predominate in a shipboard blast scenario. Even minor injuries require prolonged time before @entity1 return to active duty. Complex wounds have high infection rates and should be treated according to previously established protocols for wartime injuries. Principles of provisional @entity174 stabilization prior to transport, adequate wound d  bridement, and delayed wound closure are reviewed.

title: XXXX among survivors of USS COLE attack.

entities_list: @entity3614 :: ('MESH:D001753', 'Disease') :: ['blast injuries']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity4422 :: ('MESH:D005597', 'Disease') :: ['open fractures']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['extremity orthopaedic injuries']

answer: @entity130 :: (MESH:D014947,Disease) :: ['Orthopaedic injuries']


abstract: Virginia Stephen was a member of one of England's great literary families, many of whom were also mentally ill. An exquisitely endowed @entity1 , she was beautifully matched with her mother during the symbiotic state of development, and later called this period "the base upon which life stands." Difficulties presumably began as early as the differentiation subphase of separation. Mrs. Stephen appeared to be a narcissistic @entity1 , who required constant affirmation, and thus was unable to respond to the needs of a developing @entity1 . Virginia probably was rescued from engulfment by a powerful biologically determined practicing period of separation-individuation. This great organismic surge, in all likelihood, is as characteristic of toddlers who are incipient manics as of @entity1 of future genius. Because of the strong regressive pull, it is probable that Virginia experienced a particularly high-powered glee in evading the field of her mother. This "economic condition," according to Freud, is a given that is felt by the @entity162 as he overthrows the imprisoning restraints of the superego. Deflated by events beyond her control, such as the sadism of her siblings, Virginia probably attempted to return to her mother. But it appears that Mrs. Stephen was not available. Hence Virginia was forced to split off her anger and turn it against herself, keeping her aggression unavailable for neutralization. As a result she was unable to proceed to an age-adequate level of development. The raw rage lay smoldering within until many years later, when it burst forth to power her @entity162 attacks. This failure of rapprochement presumably deflated Virginia, and resulted in a basic mood of @entity308 already apparent in the nursery. Virginia also experienced a second basic mood, elation, which appears to have been characteristic of her even in well periods, and resembles the description of the typical @entity162 victim given by Beck.

title: Virginia Woolf: XXXX and genius. An illustration of separation-individuation theory.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'woman', 'child', 'infant']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

answer: @entity162 :: (MESH:D001714,Disease) :: ['manic-depressive psychosis']